GPER Mediates a Feedforward FGF2/FGFR1 Paracrine Activation Coupling CAFs to Cancer Cells toward Breast Tumor Progression.
Breast Neoplasms
/ metabolism
Cancer-Associated Fibroblasts
/ drug effects
Cell Line, Tumor
Cell Movement
/ drug effects
Connective Tissue Growth Factor
/ metabolism
Culture Media, Conditioned
/ pharmacology
Cyclopentanes
/ pharmacology
Disease Progression
Estradiol
/ pharmacology
Female
Fibroblast Growth Factor 2
/ metabolism
Humans
Neoplasm Invasiveness
Paracrine Communication
/ drug effects
Proto-Oncogene Proteins c-fos
/ metabolism
Quinolines
/ pharmacology
Receptor, Fibroblast Growth Factor, Type 1
/ metabolism
Receptors, Estrogen
/ metabolism
Receptors, G-Protein-Coupled
/ metabolism
Signal Transduction
/ drug effects
Up-Regulation
/ drug effects
FGF2
FGFR1
GPER
breast cancer
cancer-associated fibroblasts
estrogen
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
07 03 2019
07 03 2019
Historique:
received:
18
02
2019
revised:
01
03
2019
accepted:
04
03
2019
entrez:
15
3
2019
pubmed:
15
3
2019
medline:
15
3
2019
Statut:
epublish
Résumé
The FGF2/FGFR1 paracrine loop is involved in the cross-talk between breast cancer cells and components of the tumor stroma as cancer-associated fibroblasts (CAFs). By quantitative PCR (qPCR), western blot, immunofluorescence analysis, ELISA and ChIP assays, we demonstrated that 17β-estradiol (E2) and the G protein estrogen receptor (GPER) agonist G-1 induce the up-regulation and secretion of FGF2 via GPER together with the EGFR/ERK/c-fos/AP-1 signaling cascade in (ER)-negative primary CAFs. Evaluating the genetic alterations from METABRIC and TCGA datasets, we then assessed that FGFR1 is the most frequently amplified FGFRs family member and its amplification/expression associates with shorter survival rates in breast cancer patients. Therefore, in order to assess the functional FGF2/FGFR1 interplay between CAFs and breast cancer cells, we generated the FGFR1-knockout MDA-MB-231 cells using CRISPR/Cas9 genome editing strategy. Using conditioned medium from estrogen-stimulated CAFs, we established that the activation of FGF2/FGFR1 paracrine signaling triggers the expression of the connective tissue growth factor (CTGF), leading to the migration and invasion of MDA-MB-231 cells. Our findings shed new light on the role elicited by estrogens through GPER in the activation of the FGF2/FGFR1 signaling. Moreover, our findings may identify further biological targets that could be considered in innovative combination strategies halting breast cancer progression.
Identifiants
pubmed: 30866584
pii: cells8030223
doi: 10.3390/cells8030223
pmc: PMC6468560
pii:
doi:
Substances chimiques
1-(4-(6-bromobenzo(1,3)dioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta(c)quinolin-8-yl)ethanone
0
Culture Media, Conditioned
0
Cyclopentanes
0
GPER1 protein, human
0
Proto-Oncogene Proteins c-fos
0
Quinolines
0
Receptors, Estrogen
0
Receptors, G-Protein-Coupled
0
Fibroblast Growth Factor 2
103107-01-3
Connective Tissue Growth Factor
139568-91-5
Estradiol
4TI98Z838E
FGFR1 protein, human
EC 2.7.10.1
Receptor, Fibroblast Growth Factor, Type 1
EC 2.7.10.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
Oncogene. 2018 Sep;37(39):5340-5354
pubmed: 29858603
Nat Commun. 2016 May 10;7:11479
pubmed: 27161491
J Cell Physiol. 2009 Jul;220(1):189-95
pubmed: 19277979
Nat Rev Cancer. 2016 Aug 23;16(9):582-98
pubmed: 27550820
Exp Cell Res. 2003 Jul 1;287(1):190-8
pubmed: 12799194
Mol Cell Endocrinol. 2009 Sep 24;308(1-2):32-8
pubmed: 19464786
Neuroscience. 2016 Apr 5;319:9-22
pubmed: 26804240
Nature. 2001 May 17;411(6835):375-9
pubmed: 11357145
Clin Cancer Res. 2011 Aug 15;17(16):5275-86
pubmed: 21712446
Breast Cancer Res. 2012 Jan 17;14(1):R12
pubmed: 22251451
Tumour Biol. 2015 Mar;36(3):1385-94
pubmed: 25680413
Nat Rev Cancer. 2017 May;17(5):318-332
pubmed: 28303906
Cell Rep. 2016 Mar 15;14(10):2490-501
pubmed: 26947069
Cell. 2005 May 6;121(3):335-48
pubmed: 15882617
Proc Natl Acad Sci U S A. 2010 Dec 14;107(50):21737-42
pubmed: 21098263
Cancer Epidemiol Biomarkers Prev. 2002 Nov;11(11):1492-5
pubmed: 12433733
Nat Rev Drug Discov. 2011 Jan;10(1):47-60
pubmed: 21193867
Cancer. 2015 Jan 1;121(1):8-16
pubmed: 25043972
Semin Cell Dev Biol. 2016 May;53:126-35
pubmed: 26463732
EMBO Mol Med. 2014 Apr;6(4):467-81
pubmed: 24503018
Proc Natl Acad Sci U S A. 2008 Jun 24;105(25):8713-7
pubmed: 18552176
Int J Cancer. 2008 Nov 15;123(10):2229-38
pubmed: 18777559
Clin Cancer Res. 2014 Jun 15;20(12):3299-309
pubmed: 24771645
Cancer Discov. 2013 Mar;3(3):264-79
pubmed: 23418312
Nat Med. 2013 Nov;19(11):1423-37
pubmed: 24202395
J Endocrinol. 2010 Feb;204(2):105-14
pubmed: 19767412
Mol Cancer Res. 2012 Aug;10(8):995-1009
pubmed: 22714124
J Cell Sci. 2007 Jun 15;120(Pt 12):2053-65
pubmed: 17550972
Mol Cancer. 2018 Jan 11;17(1):5
pubmed: 29325547
Cells. 2018 Jul 15;7(7):
pubmed: 30011957
Cancer Cell. 2012 Mar 20;21(3):309-22
pubmed: 22439926
Mol Cancer. 2011 Feb 22;10:22
pubmed: 21342498
Trends Cell Biol. 2015 Apr;25(4):221-33
pubmed: 25467007
Nat Med. 2003 Aug;9(8):999-1000
pubmed: 12894162
Nature. 2004 Nov 18;432(7015):332-7
pubmed: 15549095
Oncotarget. 2017 Apr 11;8(15):24063-24076
pubmed: 28445992
Cancer Cell. 2007 Dec;12(6):559-71
pubmed: 18068632
Clin Cancer Res. 2015 Jun 15;21(12):2684-94
pubmed: 26078430
Endocr J. 2009;56(1):1-7
pubmed: 18497452
Cancer Res. 2001 Nov 15;61(22):8135-42
pubmed: 11719442
Expert Opin Ther Targets. 2015;19(10):1361-77
pubmed: 26125971
FEBS Lett. 2012 Dec 14;586(24):4270-5
pubmed: 23142580
Mol Cancer Ther. 2012 Oct;11(10):2301-5
pubmed: 22879364
Nat Rev Mol Cell Biol. 2014 Mar;15(3):178-96
pubmed: 24556840
Cell Signal. 2014 Jul;26(7):1466-75
pubmed: 24662263
Breast Cancer Res. 2018 Aug 15;20(1):97
pubmed: 30111373
Cancer Discov. 2012 May;2(5):401-4
pubmed: 22588877
Sci Rep. 2016 Apr 13;6:24354
pubmed: 27072893
Sci Rep. 2017 Aug 17;7(1):8509
pubmed: 28819120
EMBO J. 2009 Mar 4;28(5):523-32
pubmed: 19153601
Cells. 2014 Jun 10;3(2):563-91
pubmed: 24918976
Mol Carcinog. 2017 Feb;56(2):580-593
pubmed: 27341075
Cell Death Dis. 2015 Jul 30;6:e1834
pubmed: 26225773
Breast Cancer Res. 2013;15(4):R64
pubmed: 23947803
Nat Rev Cancer. 2013 Feb;13(2):97-110
pubmed: 23344542
J Cell Biol. 2008 Nov 3;183(3):543-54
pubmed: 18955554
Oncogene. 2013 Feb 7;32(6):678-88
pubmed: 22430216
EMBO J. 1998 Oct 15;17(20):5896-904
pubmed: 9774334
Mol Cancer Res. 2012 Nov;10(11):1403-18
pubmed: 23024188
Cancer Res. 2014 Aug 1;74(15):4053-64
pubmed: 24894716
Cancer Cell. 2003 Jun;3(6):537-49
pubmed: 12842083
Sci Signal. 2013 Apr 02;6(269):pl1
pubmed: 23550210
Int J Mol Med. 2016 Jul;38(1):3-15
pubmed: 27245147
Gene. 2001 Jun 27;271(2):171-82
pubmed: 11418238
Cancer Res. 2000 Dec 15;60(24):7163-9
pubmed: 11156426
Nat Protoc. 2013 Nov;8(11):2281-2308
pubmed: 24157548
Biofactors. 2009 Mar-Apr;35(2):200-8
pubmed: 19449449
Cells. 2018 Dec 08;7(12):
pubmed: 30544798
Mol Cancer Ther. 2016 Sep;15(9):2096-106
pubmed: 27371729
Cells. 2018 Oct 05;7(10):
pubmed: 30301152
J Pathol. 2003 Jul;200(4):429-47
pubmed: 12845611
Curr Cancer Drug Targets. 2012 Jun;12(5):531-42
pubmed: 22414008
Cells. 2018 Nov 09;7(11):
pubmed: 30423928
Biochim Biophys Acta. 2013 Jul;1832(7):1070-8
pubmed: 23123598
Best Pract Res Clin Endocrinol Metab. 2015 Aug;29(4):557-68
pubmed: 26303083
Front Oncol. 2014 Mar 27;4:62
pubmed: 24734219
Nature. 2012 Apr 18;486(7403):346-52
pubmed: 22522925